Printer Friendly

New Venture Funding for Alzheimer's Disease Drug Developer.

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder. The company has raised $7.4 million to date in equity funding.

Venture Investors (VI - Madison, Wis.) led this latest round of financing. The State of Wisconsin Investment Board and Wisconsin Investment Partners, both of Madison, Wis., and Rocket Venture Fund (Toledo. Ohio), all existing shareholders, also participated in the latest funding. Mithridion plans to hold a final closing with respect to this financing on or before March 31, 2009.

John Neis, Managing Director of VI, will join Mithridion's board of directors.

"This new funding will enable Mithridion not only to advance MCD-386 in Phase I trial, but will also support the development of exciting drug leads for AD and schizophrenia in our preclinical pipeline," said Trevor M. Twose, Ph.D., the company's Chief Executive. "We greatly appreciate the continued support of our shareholders," he added.

Five million Americans suffer from Alzheimer's disease today, and the number will grow as baby-boomers age. The market for Alzheimer's disease drugs exceeds $4 billion, but is currently underserved, and may grow to greater than $10 billion with the development of drugs that are more effective.

MCD-386 is highly selective for the M1-type muscarinic receptor. In preclinical laboratory tests, MCD-386 appears to replace deficient brain acetylcholine activity, similar to that caused by AD. This drug is intended to improve memory and cognition, with improved tolerability compared to previously tested M1-selective muscarinic drugs. MCD-386 also appeared to activate alpha-secretase enzymes, which might reduce or prevent the loss of brain cells in AD by preventing the formation of amyloid beta. In preclinical laboratory tests, MCD-386 appeared to be superior to the best first-generation drug candidates of this type.

Four of the five currently approved drugs slow down the breakdown of acetylcholine, thereby boosting its concentration to overcome the deficiency in AD. However, unlike these drugs, MCD-386 is designed to mimic only the M1 activity of acetylcholine, with potentially greater efficacy and less side-effects.

Mithridion's headquarters and preclinical drug research laboratories are in Madison, Wis., and its semi-virtual clinical drug development team operates out of Toledo, Ohio. The Company commenced operations in February 2006. During 2008, Mithridion acquired Cognitive Pharmaceuticals Ltd., (Toledo, Ohio), raised $2.3 million of Series B funding, and successfully completed the first stage of Phase I clinical trials of MCD-386.

Venture Investors is a venture capital firm with $190 million under management. The firm invests in seed and early-stage life science and technology companies in the Midwest, with a primary focus on opportunities that spin out of the region's leading research universities. Formed in 1982, Venture Investors has offices strategically located next to the country's third and fourth largest research institutions in Ann Arbor, Mich., and Madison, Wisc. For additional information on the firm, visit http://www.ventureinvestors.com/.

CONTACT: Trevor M Twose, Chief Executive Officer of Mithridion, Inc., Cell, +1-608-332-8319; or Paul M Weiss PhD MBA, Venture Investors LLC, Cell, +1-608-445-8960

Web Site: http://www.mithridion.com/ http://www.ventureinvestors.com/
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 2009
Words:562
Previous Article:Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline.
Next Article:Chiasma Provides Updates on Scientific Achievements, Financing, Management and Facilities.


Related Articles
MITOKOR COMPLETES $10.6 MILLION VENTURE CAPITAL FUNDING
Beyond Genomics Forms Alzheimer's Disease Joint Venture with Elan Corporation.
Institute for the Study of Aging Funds Helicon Therapeutics To Test New Treatments for Dementia.
Institute for the Study of Aging Announces Winner of the First Alzheimer's Disease Drug Discovery Award; Award Recognizes That Seed Capital Funding...
Zapaq Completes $6 Million Financing.
Institute for the Study of Aging Receives Generous Donation from Elan Pharmaceuticals to Create a New Alzheimer's Disease Research Program.
Avid RP Closes $8.9 Million Financing to Support Development of Alzheimer's Diagnostic and Prognostic Agents.
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters